All Immuno-oncology articles – Page 6
-
WebinarComplete CAR-T workflow solutions for research
Watch this webinar to get an overview of the CAR-T workflow and learn about the latest CAR-T research enabling tools that can accelerate your discovery.
-
ArticleBiochemical assays and deep cyclic inhibition in cancer treatment
Drug Target Review's Taylor Mixides exclusively interviews Brett Hall, Chief Scientific Officer at Immuneering, about his company’s aim to develop a universal-RAS therapy.
-
ArticleT cells' vital role in boosting immune responses
In this article, Drug Target Review's Izzy Wood uncovers the cutting-edge breakthroughs in T cell research that are revolutionising our understanding of the immune system and paving the way for new therapies and treatments.
-
NewsCombination therapy effective against canine melanoma
A combination of radiotherapy followed by immunotherapy is a promising strategy for the treatment of oral malignant melanomas in dogs.
-
ArticleChemotherapy-free treatment for patients with blood cancer
Dr Andy Souers highlights the unwavering commitment to finding an enhanced therapeutic approach that eliminates the need for chemotherapy in blood cancer treatment. This transformative discovery represents a significant leap forward in the way we combat this complex disease, offering new hope to countless patients worldwide.
-
ArticleTargeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering
In this article Dr Raymond Winquist, Oncology Fellow at Alkermes, covers the longstanding research challenges associated with cytokines: IL-12 and IL-18, and their untapped potential in immunotherapy and immuno-oncology.
-
NewsCustomising T cell-based immunotherapies to treat cancers
US researchers usings a ‘SNAP’ receptor system can customise immunotherapies for targeted treatments of cancer and other diseases.
-
NewsAnalysis of 33 tumour types identifies new immunotherapy targets
The researchers identified 1,068 transposable element-derived transcripts with the potential to produce tumour antigens that could serve as targets for new immunotherapies.
-
WebinarAccelerating biologics discovery via antibody library and reaching IND faster with cell line development
The application of Fab and VHH naïve library to expedite the antibody discovery against tumor-associated antigen for CAR-T, ADC and bispecific antibody.
-
NewsGround-breaking glycocalyx study could improve cancer immunotherapy
The researchers found that cancer cells with thicker glycocalyx barrier are better at evading immune cells.
-
Whitepaper
Whitepaper: Serum-free and Animal-free Research
Discover how the adoption of animal-free media/supplements can improve reproducibility in cell culture and biotherapeutic research.
-
WhitepaperWhitepaper: PSMA Protein in the Battle Against Cancer
The PSMA Protein is a new therapeutic hot target. In this article, learn about its growing role in the fight against prostate cancer and beyond.
-
NewsStopping immune cell leakage from tumours could improve skin cancer treatment
Results show the number of specialised immune cells available for fighting skin cancer doubled when a new treatment blocked their escape from melanoma tumours.
-
ArticleTransforming the way cancer vaccines are designed and made
Researchers found that ‘rational vaccinology’ increases potency by changing the structural location of antigens and adjuvants.
-
NewsDiscovery of CAFs’ origin gives new direction for pancreatic cancer
US researchers discovered a type of cell involved it pancreatic cancer and sheds light on the origin of cancer-associated fibroblasts (CAFs).
-
ArticleDeveloping state-of‑the‑art CAR T-cell therapy for cancer treatment
In this Q&A, Dr Frank Neumann speaks about Kite Pharma’s work with chimeric antigen receptor (CAR) T-cell therapy and how the company is working to progress this next‑generation modality even further to help treat cancer patients.
-
ArticleAllogeneic CAR T-cell therapy: the future of cancer care
In this Q&A, Dr Devon Shedlock discusses Poseida Therapeutics' cancer treatment pipeline and the advances it has made towards developing chimeric antigen receptor (CAR) T-cell therapies for liquid and solid tumours.
-
Article
The next wave: going beyond CAR T cells with cell-based therapies
In this article, Dr Daniel Teper and Dr Chris Arendt explore cellular therapies for cancer that provide an alternative to chimeric antigen receptor (CAR) T-cell therapy. In these Q&As, they outline their important work in immuno-oncology.
-
Article
The advantages of gamma-delta T-cell therapy
Here, Dr Michael Leek describes the benefits of gamma-delta T cells for cancer therapy, exploring why they present a potential alternative to other immuno-oncology platforms.
-
ArticleWhen exhausted, cancer-fighting T cells may switch sides
Using flow cytometry, Dr Greg Delgoffe and Dr Paolo Vignali highlight that low oxygen environment of tumours can prompt exhausted T cells to suppress the immune system instead of combating cancer.